| Name | Title | Contact Details |
|---|
Accountable Health Partners is a network of hospitals and doctors focused on improving healthcare quality while rewarding doctors for the value and exceptional outcomes they create.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
It`s good to be home! Jet Health is a provider of skilled home health, hospice, personal care, and companion services. Founded in April 2016, Jet Health is building a national platform through organic growth, strategic acquisitions, and de novo build-outs in target markets. These markets are typically mid-sized cities that have under served and growing Medicare populations. Jet Health leverages local brands and operating expertise while sharing best practices across its companies and centralizes traditional back office functions. The company believes that its four cornerstones: superior service, clinical excellence, compliant business practices and an employee centric environment, provide a solid foundation upon which to build a successful company in the home health marketplace.
Lipid Nutrition is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Eastern Connecticut Health Network, Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Eastern Connecticut Health Network, Inc. is based in Manchester, CT. You can find more information on Eastern Connecticut Health Network, Inc. at www.echn.org